Multiple mechanisms underlying the neuroprotective effects of antiepileptic drugs against in vitro ischemia

Stroke

Volumn 37, Issue 5, 2006, Pages 1319-1326

  Costa, Cinzia ^a,b   Martella, Giuseppina ^b,c   Picconi, Barbara ^b,c   Prosperetti, Chiara ^b,c   Pisani, Antonio ^b,c   Di Filippo, Massimiliano ^a,b   Pisani, Francesco ^d   Bernardi, Giorgio ^b,c   Calabresi, Paolo ^a,b  

^a UNIVERSITY OF PERUGIA   (Italy)

^b IRCCS FONDAZIONE SANTA LUCIA   (Italy)

^c UNIVERSITY OF ROME TOR VERGATA   (Italy)

^d UNIVERSITY OF MESSINA   (Italy)

Author keywords

Antiepileptic drugs; Ca 2+; Electrophysiology; Ischemia; Na 2+

Indexed keywords

ANTICONVULSIVE AGENT; CALCIUM ION; CARBAMAZEPINE; ETIRACETAM; GLUCOSE; GLUTAMIC ACID; LAMOTRIGINE; NIMODIPINE; OXYGEN; REMACEMIDE; SODIUM ION; TIAGABINE; TOPIRAMATE; VALPROIC ACID; VIGABATRIN;

ADOLESCENT; ANIMAL TISSUE; ARTICLE; BRAIN ELECTROPHYSIOLOGY; BRAIN ISCHEMIA; CALCIUM CONDUCTANCE; CALCIUM CURRENT; CEREBROSPINAL FLUID; CONTROLLED STUDY; CORPUS STRIATUM; DRUG MECHANISM; EXCITATORY POSTSYNAPTIC POTENTIAL; FACILITATION; IN VITRO STUDY; MICROELECTRODE; NEUROPROTECTION; NEUROTRANSMISSION; NONHUMAN; PATCH CLAMP; PRESYNAPTIC INHIBITION; PRIORITY JOURNAL; RAT; SODIUM CONDUCTANCE; SODIUM CURRENT;

ANIMALS; ANTICONVULSANTS; BRAIN ISCHEMIA; CALCIUM SIGNALING; CARBAMAZEPINE; ELECTROPHYSIOLOGY; EXCITATORY POSTSYNAPTIC POTENTIALS; FRUCTOSE; ION TRANSPORT; POTASSIUM; RATS; VALPROIC ACID;

EID: 33646701918     PISSN: 00392499     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.STR.0000217303.22856.38     Document Type: Article

References (35)

1. Lo EH, Dalkara T, Moskowitz MA. Mechanisms, challenges and opportunities in stroke. Nat Rev Neurosci. 2003;4:399-415.
2. Calabresi P, Centonze D, Bernardi G. Cellular factors controlling neuronal vulnerability in the brain: a lesson from the striatum. Neurology. 2000;55:1249-1255.
3. Calabresi P, Centonze D, Pisani A, Cupini L, Bernardi G. Synaptic plasticity in the ischaemic brain. Lancet Neurol. 2003;2:622-629.
4. Calabresi P, Cupini LM, Centonze D, Pisani F, Bernardi G. Antiepileptic drugs as a possible neuroprotective strategy in brain ischemia. Ann Neurol. 2003;53:693-702.
5. Leker RR, Neufeld MY. Anti-epileptic drugs as possible neuroprotectants in cerebral ischemia. Brain Res Brain Res Rev. 2003;42:187-203.
6. Centonze D, Marfia GA, Pisani A, Picconi B, Giacomini P, Bernardi G, Calabresi P. Ionic mechanisms underlying differential vulnerability to ischemia in striatal neurons. Prog Neurobiol. 2001;63:687-696.
7. Calabresi P, Saulle E, Centonze D, Pisani A, Marfia GA, Bernardi G. Post-ischaemic long-term synaptic potentiation in the striatum: a putative mechanism for cell type-specific vulnerability. Brain. 2002;125:844-860.
8. Rogawski MA, Loscher W. The neurobiology of antiepileptic drugs. Nat Rev Neurosci. 2004;5:553-564.
9. Calabresi P, Picconi B, Saulle E, Centonze D, Hainsworth AH, Bernardi G. Is pharmacological neuroprotection dependent on reduced glutamate release? Stroke. 2000;31:766-772.
10. Costa C, Leone G, Saulle E, Pisani F, Bernardi G, Calabresi P. Coactivation of GABA(A) and GABA(B) receptor results in neuroprotection during in vitro ischemia. Stroke. 2004;35:596-600.
11. Calabresi P, Marti M, Picconi B, Saulle E, Costa C, Centonze D, Pisani F, Bernardi G. Lamotrigine and remacemide protect striatal neurons against in vitro ischemia: an electrophysiological study. Exp Neurol. 2003;182:461-469.
12. Rogawski MA, Loscher W. The neurobiology of antiepileptic drugs for the treatment of nonepileptic conditions. Nat Med. 2004;10:685-692.
13. Calabresi P, Centonze D, Pisani A, Sancesario G, Gubellini P, Marfia GA, Bernardi G. Striatal spiny neurons and cholinergic interneurons express differential ionotropic glutamatergic responses and vulnerability: implications for ischemia and Huntington's disease. Ann Neurol. 1998;43:586-597.
14. Calabresi P, Stefani A, Marfia GA, Hainsworth AH, Centonze D, Saulle E, Spadoni F, Leach MJ, Giacomini P, Bernardi G. Electrophysiology of sipatrigine: a lamotrigine derivative exhibiting neuroprotective effects. Exp Neurol. 2000;162:171-179.
15. Stefani A, Hainsworth AH, Spadoni F, Bernardi G. On the inhibition of voltage activated calcium currents in rat cortical neurones by the neuroprotective agent 619C89. Br J Pharmacol. 1998;125:1058-1064.
16. Stefani A, Spadoni F, Bernardi G. Gabapentin inhibits calcium currents in isolated rat brain neurons. Neuropharmacology. 1998;37:83-91.
17. Thomson AM. Facilitation, augmentation and potentiation at central synapses. Trends Neurosci. 2000;23:305-312.
18. Lindberger M, Tomson T, Lars S. Microdialysis sampling of carbamazepine, phenytoin and phenobarbital in subcutaneous extracellular fluid and subdural cerebrospinal fluid in humans: an in vitro and in vivo study of adsorption to the sampling device. Pharmacol Toxicol. 2002;91:158-165.
19. Christensen J, Hojskov CS, Dam M, Poulsen JH. Plasma concentration of topiramate correlates with cerebrospinal fluid concentration. Ther Drug Monit. 2001;23:529-535.
20. Davis R, Peters DH, McTavish D. Valproic acid. A reappraisal of its pharmacological properties and clinical efficacy in epilepsy. Drugs. 1994;47:332-372.
21. Ren M, Leng Y, Jeong M, Leeds PR, Chuang DM. Valproic acid reduces brain damage induced by transient focal cerebral ischemia in rats: potential roles of histone deacetylase inhibition and heat shock protein induction. J Neurochem. 2004;89:1358-1367.
22. Mora A, Gonzalez-Polo RA, Fuentes JM, Soler G, Centeno F. Different mechanisms of protection against apoptosis by valproate and Li+. Eur J Biochem. 1999;266:886-891.
23. Eyal S, Yagen B, Sobol E, Altschuler Y, Shmuel M, Bialer M. The activity of antiepileptic drugs as histone deacetylase inhibitors. Epilepsia. 2004;45:737-744.
24. Hanon E, Klitgaard H. Neuroprotective properties of the novel antiepileptic drug levetiracetam in the rat middle cerebral artery occlusion model of focal cerebral ischemia. Seizure. 2001;10:287-293.
25. Marini H, Costa C, Passaniti M, Esposito M, Campo GM, Ientile R, Adamo EB, Marini R, Calabresi P, Altavilla D, Minutoli L, Pisani F, Squadrito F. Levetiracetam protects against kainic acid-induced toxicity. Life Sci. 2004;74:1253-1264.
26. Lukyanetz EA, Shkryl VM, Kostyuk PG. Selective blockade of N-type calcium channels by levetiracetam. Epilepsia. 2002;43:9-18.
27. Pisani A, Bonsi P, Martella G, De Persis C, Costa C, Pisani F, Bernardi G, Calabresi P. Intracellular calcium increase in epileptiform activity: modulation by levetiracetam and lamotrigine. Epilepsia. 2004;45:719-728.
28. Pisani A, Bonsi P, Calabresi P. Calcium signaling and neuronal vulnerability to ischemia in the striatum. Cell Calcium. 2004;36:277-284.
29. Kobayashi T, Mori Y. Ca2+ channel antagonists and neuroprotection from cerebral ischemia. Eur J Pharmacol. 1998;363:1-15.
30. Pisani A, Calabresi P, Tozzi A, D'Angelo V, Bernardi G. L-type Ca2+ channel blockers attenuate electrical changes and Ca2+ rise induced by oxygen/glucose deprivation in cortical neurons. Stroke. 1998;29:196-201.
31. Zona C, Niespodziany I, Marchetti C, Klitgaard H, Bernardi G, Margineanu DG. Levetiracetam does not modulate neuronal voltage-gated Na+ and T-type Ca2+ currents. Seizure. 2001;10:279-286.
32. Bargas J, Howe A, Eberwine J, Cao Y, Surmeier DJ. Cellular and molecular characterization of Ca2+ currents in acutely isolated, adult rat neostriatal neurons. J Neurosci. 1994;14:6667-6686.
33. Taylor CP, Burke SP, Weber ML. Hippocampal slices: glutamate overflow and cellular damage from ischemia are reduced by sodium-channel blockade. J Neurosci Meth. 1995;59:121-128.
34. Waugh J, Goa KL. Topiramate: as monotherapy in newly diagnosed epilepsy. CNS Drugs. 2003;17:985-992.
35. Yang Y, Shuaib A, Li Q, Siddiqui MM. Neuroprotection by delayed administration of topiramate in a rat model of middle cerebral artery embolization. Brain Res. 1998;804:169-176.